Exhibit 4(g) Amendment renewing the IMMUNITY AGREEMENT entered into January 25, 1994 between Motorola, Inc. and ASE, Incorporated Motorola Inc. and ASE, Incorporated agree to amend the above-identified IMMUNITY AGREEMENT as follows: In Section 1.4,...Immunity Agreement • June 30th, 2004 • Advanced Semiconductor Engineering Inc • Semiconductors & related devices
Immunity AgreementImmunity Agreement • September 25th, 2003 • Tessera Technologies Inc • Semiconductors & related devices • California
This Agreement (hereafter “Agreement”) is entered into as of the day of January, 2002 (“Effective Date”), between TESSERA INC., a corporation organized under the laws of Delaware, having a principal place of business at 3099 Orchard Drive, San Jose, CA, 95134, USA and the Tessera Affiliates (“Tessera”) and SHARP CORPORATION, a corporation organized under the laws of Japan having a principal place of business at 22-22 Nagaike-cho, Abeno-ku, Osaka 545-8522 Japan and the Sharp Affiliates (“Sharp”) with reference to the following facts:
SECOND AMENDMENT TO IMMUNITY AGREEMENTImmunity Agreement • March 7th, 2008 • Stats Chippac Ltd. • Semiconductors & related devices
Whereas Motorola Inc., (“MOTOROLA”) and ST Assembly Test Services, Ltd. (“STATS”) entered into an Immunity Agreement on October 18, 1996 involving BGA packages (“IMMUNITY AGREEMENT”);
AMENDMENT TO IMMUNITY AGREEMENTImmunity Agreement • August 11th, 2004 • Tessera Technologies Inc • Semiconductors & related devices
This Amendment (“Amendment”) is entered into as of this 6th day of July, 2004 (“Amendment Execution Date”) by and between TESSERA, INC. (“Tessera”) and SHARP CORPORATION (“Sharp”), and amends the Immunity Agreement (“Agreement”) entered into by and between the parties having an Effective Date of January 24, 2002. Both parties agree that any and all terms and conditions of this Amendment deem to be effective on and after April 1, 2004 (“Amendment Effective Date”).
Immunity Agreement: Re-engineering the Immune Response to Treat Pancreas CancerImmunity Agreement • June 3rd, 2014
Human cell lines in immune- Patient-derived GEMM of GEMM of deficient host (murine cells can be tumor pieces in spontaneous spontaneous
